MXPA02012924A - Nuevas variantes moleculares terapeuticas y sus usos. - Google Patents

Nuevas variantes moleculares terapeuticas y sus usos.

Info

Publication number
MXPA02012924A
MXPA02012924A MXPA02012924A MXPA02012924A MXPA02012924A MX PA02012924 A MXPA02012924 A MX PA02012924A MX PA02012924 A MXPA02012924 A MX PA02012924A MX PA02012924 A MXPA02012924 A MX PA02012924A MX PA02012924 A MXPA02012924 A MX PA02012924A
Authority
MX
Mexico
Prior art keywords
sphingosine
variants
present
novel therapeutic
molecular variants
Prior art date
Application number
MXPA02012924A
Other languages
English (en)
Inventor
Binks Wattenberg
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ8408A external-priority patent/AUPQ840800A0/en
Priority claimed from AUPQ8699A external-priority patent/AUPQ869900A0/en
Priority claimed from AUPQ9980A external-priority patent/AUPQ998000A0/en
Priority claimed from AUPR2749A external-priority patent/AUPR274901A0/en
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of MXPA02012924A publication Critical patent/MXPA02012924A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01091—Sphinganine kinase (2.7.1.91)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere generalmente a una variante de quinasa esfingosina y a los derivados, analogos, equivalentes quimicos e imitadores de la misma que muestren actividad catalitica reducida y, mas particularmente, a las variantes de quinasa esfingosina que muestren una capacidad reducida a esfingosina fosforilato a esfingosina-1-fosfato. La presente invencion tambien contempla las secuencias geneticas que codifican dichas variantes de quinasa esfingosina y los derivados, analogos e imitadores de la misma. Las variantes de la presente invencion son utiles en un rango de aplicaciones terapeuticas y profilacticas.
MXPA02012924A 2000-06-28 2001-06-20 Nuevas variantes moleculares terapeuticas y sus usos. MXPA02012924A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPQ8408A AUPQ840800A0 (en) 2000-06-28 2000-06-28 Novel therapeutic molecular variants and uses thereof
AUPQ8699A AUPQ869900A0 (en) 2000-07-11 2000-07-11 Novel therapeutic molecular variants and uses thereof - ii
AUPQ9980A AUPQ998000A0 (en) 2000-09-08 2000-09-08 Novel therapeutic molecular variants and uses thereof-iii
AUPR2749A AUPR274901A0 (en) 2001-01-29 2001-01-29 Novel therapeutic molecular variants and uses thereof - IV
PCT/AU2001/000730 WO2002000887A1 (en) 2000-06-28 2001-06-20 Novel therapeutic molecular variants and uses thereof

Publications (1)

Publication Number Publication Date
MXPA02012924A true MXPA02012924A (es) 2004-07-30

Family

ID=27424515

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012924A MXPA02012924A (es) 2000-06-28 2001-06-20 Nuevas variantes moleculares terapeuticas y sus usos.

Country Status (11)

Country Link
US (1) US20080279841A1 (es)
EP (1) EP1299548A4 (es)
JP (1) JP2004500903A (es)
CN (1) CN1444654A (es)
BR (1) BR0112059A (es)
CA (1) CA2414210A1 (es)
IL (1) IL153653A0 (es)
MX (1) MXPA02012924A (es)
NO (1) NO20026265L (es)
NZ (1) NZ523343A (es)
WO (1) WO2002000887A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514828A (ja) * 2002-10-14 2006-05-18 メドベット・サイエンス・プロプライエタリー・リミテッド スフィンゴシンキナーゼの機能的レベルを調節することによって上皮細胞活性を調節する方法
AU2003901270A0 (en) * 2003-03-18 2003-04-03 Medvet Science Pty. Ltd. A method of modulating muscle cell functioning
AU2004221792C1 (en) * 2003-03-18 2009-09-24 Medvet Science Pty. Ltd. A method of modulating smooth muscle cell functioning by modulating sphingosine kinase mediated signalling

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AU4097999A (en) * 1998-05-26 1999-12-13 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
DE60027295T2 (de) * 1999-05-13 2007-01-18 Johnson & Johnson Pharmaceutical Research & Development, Llc Sphingosinekinase
WO2001031029A2 (en) * 1999-10-28 2001-05-03 Warner-Lambert Company Human sphingosine kinase gene

Also Published As

Publication number Publication date
JP2004500903A (ja) 2004-01-15
CA2414210A1 (en) 2002-01-03
WO2002000887A1 (en) 2002-01-03
BR0112059A (pt) 2004-07-27
NO20026265D0 (no) 2002-12-27
US20080279841A1 (en) 2008-11-13
IL153653A0 (en) 2003-07-06
EP1299548A4 (en) 2004-12-01
NZ523343A (en) 2005-03-24
NO20026265L (no) 2003-02-24
EP1299548A1 (en) 2003-04-09
CN1444654A (zh) 2003-09-24

Similar Documents

Publication Publication Date Title
EP2292784A3 (en) Enzymes having alpha amylase activity and methods of use thereof
EP1192247A4 (en) SPHINGOSINEKINASE
EP2264160A3 (en) Alpha-amylase variant with altered properties
YU68002A (sh) Modifikovani faktor viii
WO2003048205A3 (fr) Proteines a activite inhibitrice de l'il-6
MXPA02012924A (es) Nuevas variantes moleculares terapeuticas y sus usos.
TWI266775B (en) Polyacrylic acid hydrazide and crosslinking or hardening agent for resin
HK1096423A1 (en) Isolated luciferases and the use thereof
MXPA03005350A (es) Poliisocianatos bloqueados basados en hexametilendiisocianato.
EP1480992A4 (en) TELOMERASEINTERFERENZ
AU2002217062A1 (en) Dental compounds with reduced temperature sensitivity
WO2001081556A3 (en) Enzyme variants having one or more d-amino acid substitutions
WO2002102991A3 (en) Crystals and structure of 2c-methyl-d-erythritol 2,4-cyclodiphosphate synthase mecps
MXPA02003360A (es) Transacilasas de la ruta biosintetica de paclitaxel.
WO2003035878A3 (de) Lipase-varianten
WO2003027314A3 (en) Protected linker compounds
ZA200401116B (en) Permeabilisation of cells.
AU1192102A (en) Haplotypes of the cyp1b1 gene
EP1434813A4 (en) POLYMERS AND OLIGOMERS, THEIR SYNTHESIS AND ITS CONTAINING ELECTRONIC COMPONENTS
WO2003054009A3 (de) Apoptotisch wirksame peptide
DE60216920D1 (en) Tryptase-inhibitoren
WO2001088108A8 (de) Neuronale serin-threonin-protein-kinase
WO2002048333A3 (en) Novel human kinases and uses thereof
NZ505980A (en) Beta-sheet mimetics
ATE221895T1 (de) Chimäre oligonucleotide und ihre verwendung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal